Company Overview
Artiva Biotherapeutics, Inc. operates as a clinical-stage biotechnology entity dedicated to the development of natural killer (NK) cell-based therapies designed to treat patients suffering from autoimmune diseases and various forms of cancer. The company's primary focus lies in creating off-the-shelf NK cell solutions, with its lead product candidate, AlloNK, specifically targeting the autoimmune disease market where immediate access to therapy is critical. This biotechnology firm functions within the broader Healthcare sector, specifically navigating the highly competitive and research-intensive Biotechnology industry, which implies a reliance on continuous innovation and regulatory approval processes rather than established product sales. As of the latest available data, the company holds a market capitalization of $134.95M and employs a workforce of 104 individuals, reflecting a mid-sized operational structure typical of late-stage clinical companies. The combination of a relatively modest market cap and the absence of reported annual revenue figures indicates that Artiva is still in a phase where capital allocation is directed toward research and development activities rather than generating significant commercial income or operating profits.
Financial Health
The company reports a net income of $-83,865,000 for the trailing twelve-month period, while revenue and earnings growth figures are not currently available, suggesting that traditional profitability metrics are not yet realized in the commercial phase. The EBITDA for the same period stands at $-87,213,000, creating a significant negative gap relative to any potential future revenue that would indicate a cost structure currently dominated by research expenses rather than production or sales costs. Free cash flow is reported at $-49,240,248, which signifies that the company is consuming cash to fund its clinical trials and operational expansion, thereby limiting immediate financial flexibility but necessary for asset development. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard presentation for clinical-stage firms where revenue is negligible compared to the substantial fixed and variable costs of bringing a drug to market. The balance sheet shows a cash position of $108.01M against total debt of $10.94M, resulting in a debt-to-equity ratio of 9.95, which illustrates a leveraged capital structure where equity financing has been utilized to manage obligations without relying heavily on interest-bearing debt. Despite the high debt-to-equity figure, the current ratio of 8.61 indicates robust short-term liquidity, suggesting the company possesses ample current assets to cover its current liabilities without immediate distress. Return on Equity is -56.5% and Return on Assets is -33.0%, metrics that reveal that management is currently deploying capital to generate losses associated with clinical progression rather than generating returns on the existing asset base.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -2.20, a valuation metric that implies the market is pricing in future earnings recovery that has not yet materialized in the current financial statements. The price-to-book ratio stands at 1.21, indicating that the market values the company at a slight premium over its net book value, reflecting the intangible value of its pipeline and intellectual property despite current losses. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -0.43, suggest that traditional multiple-based comparisons are less relevant for a company without positive sales or earnings, shifting valuation focus to cash burn rates and clinical milestones. The stock has traded between a 52-week high of $7.75 and a 52-week low of $1.47, meaning the current price sits within a wide historical range that captures both periods of high investor optimism and significant market correction. The beta value is not available, which limits the ability to quantify the stock's price volatility relative to the broader market index based on historical price movements provided in the dataset.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company has not yet established a consistent commercial trajectory where growth rates can be meaningfully calculated against prior periods. Because the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that all available earnings are theoretically reinvested into research and development rather than distributed to shareholders. The absence of a dividend policy aligns with the strategic necessity of clinical-stage biotechnology companies to retain capital for operational needs and clinical trial funding rather than providing income to investors. The overall growth and income profile is characterized by a complete lack of current commercial growth metrics and no income distribution, reflecting a business model entirely dependent on successful clinical outcomes to transition from a research entity to a revenue-generating commercial platform.